NEW YORK (TheStreet) -- CHANGE IN RATINGS
downgraded at Baird to Neutral. Valuation call, as the stock is up more than 40% over the past month.
upgraded at Susquehanna. BHI was upgraded from Neutral to Positive. $53 price target. Recent pullback has created a buying opportunity in the potential turnaround play.
( CBE) rated new Buy at Deutsche Bank. $60 price target. Company is a pure-play in electrical equipment and can grow its margins in the new order cycle. Buy rating.
upgraded at Goldman from Neutral to Buy. Stock was also added to the Conviction List, with a $110 price target. Company should benefit from growth in the nitrogen and phosphate markets.
initiated at Barclays. CN initiated with an Equal Weight rating and $70 price target. CN is the most profitable of North America railroads and well positioned to capitalize on recovery.
upgraded at Stifel from Hold to Buy. $36 price target. Stock appears oversold, following the 20% post-earnings selloff.
Canadian Pacific Railway
initiated at Barclays with an Equal Weight rating and C$68 price target. Several factors leave CP less profitable then industry.
downgraded at JP Morgan. DLTR was downgraded from Neutral to Underweight. Valuation call, as the stock has more than doubled since the beginning of 2008.
upgraded at Stifel from Hold to Buy. $40 price target. Stock is down 17% over the past four months, even though the company had a good quarter.
initiated at BofA/Merrill. NGD coverage initiated at Bank of America/Merrill Lynch with a Buy rating and C$7.65 price target. Solid gold production growth and improving cash costs.
downgraded at BMO from Outperform to Market Perform. Valuation call, based on a $17 price target.
upgraded at BofA/Merrill to Buy from Neutral as momentum could improve given increasing support from P-Fresh store conversions. Price target increased to $61 from $56.
upgraded at BMO to Outperform. $33 price target. Company is positioned well for solid earnings over the new few years.
downgraded at Goldman from Buy to Neutral. Company is seeing lower paint demand and being hurt by higher raw material costs. $33 price target.
STOCK COMMENTS / EPS CHANGES
price target decreased at Credit Suisse to $36 from $40. Solid 3Q10 results, EMG segment is not seeing a slowdown in any end markets or geographies. Maintain Outperform rating.
estimates increased at Jefferies through 2012. Company has significant operating leverage. Buy rating and $42 price target.
price target lower at Barclays. BHI price target trimmed to $43 from $46. International margins remain weak. Reiterate Equal Weight rating.
estimates, target raised at Jefferies. Shares of BRKR now seen reaching $15.50. Estimates also increased, as the company should benefit from stimulus initiatives across the globe. Hold rating.
estimates, target increased at Goldman. CCL estimates were raised through 2012. Company is seeing lower fuel prices. Neutral rating and new $36 price target.
numbers cut at UBS. Shares of CNX now seen reaching $67. Estimates also lowered, given lower expected natural gas prices. Buy rating.
price target boosted at BofA/Merrill. CRM price target raised to $120 from $100. Improvement in business ton and better bookings. Reiterate Buy rating.
numbers cut at Goldman. Shares of EDMC now seen reaching $10. Estimates also lowered, given lower loan repayment rates. Neutral rating.
price target raised at BofA/Merrill to $44 from $39. Expecting strong 4Q10 results. Maintain Buy rating.
price target lower at Credit Suisse by a dollar to $10. Credit quality prospects positive but loan demand remains low. Maintain Outperform rating.
estimates, target raised at Citigroup. Shares of LOW now seen reaching $22. Estimates also increased, given higher realized margins. Hold rating.
estimates upped at Jefferies. LOW estimates were boosted through 2012. Management is realizing higher margins, despite softer sales. Buy rating and $24 price target.
Medco Health Solutions
price target cut at BofA/Merrill to $70 from $74 as the company acquires United BioSource. Maintain Buy rating.
estimates reduced at Morgan Stanley. NFLX estimates were cut through 2012. EPIX deal could pressure margins, but still makes strategic sense. Overweight rating.
( SII) price target boosted at Barclays. SII price target increased to $56 from $52 as earnings estimates improve. 2010 and 2011 EPS estimates lifted to $1.15 and $1.65, respectively. Maintain Equal Weight rating.
estimates boosted at UBS. URBN estimates were upped through 2012. Company is executing well in a choppy environment. Buy rating and $45 price target.
target lowered at Piper. Shares of URBN now seen reaching $35. Core stores are lagging the other concepts and management has limited sales visibility. Neutral rating.
This article was written by a staff member of TheStreet.